NCEL
NewcelX Ltd.
$3.23
-1.10%
$17.4M
No data for this timeframe.
Vol
Market Cap$17.4M
Cap SizeNano Cap
SEC Reports6
Press Releases2
Recent Activity
Jun 5, 2026
SEC
NewcelX Ltd. filed a 6-K furnishing the notice of meeting and proxy card for its Annual General Shareholders' Meeting sc
6-K — Impact 4/10
May 27, 2026
Press
NewcelX announced submission of a Pre-IND briefing package to the FDA for NCEL-101 (stem-cell-derived islet therapy) com
Impact 5/10
May 27, 2026
announcement
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
<p align="center"><i>Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatmen
May 18, 2026
SEC
NewcelX Ltd.'s F-3 shelf registration (File No. 333-295770) became effective on May 15, 2026, allowing the company to of
EFFECT — Impact 5/10
May 7, 2026
SEC
NewcelX Ltd.'s shelf registration statement (File No. 333-290516) became effective on May 6, 2026, allowing the company
EFFECT — Impact 3/10
Apr 20, 2026
Press
NewcelX announced an updated corporate presentation highlighting its strategic collaboration with Eledon Pharmaceuticals
Impact 5/10
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Latest Reports
NEUTRAL
6-K
4/10
NewcelX Ltd. filed a 6-K furnishing the notice of meeting and proxy card for its Annual General Shareholders' Meeting sc
Jun 5, 2026
NEUTRAL
Press
5/10
NewcelX announced submission of a Pre-IND briefing package to the FDA for NCEL-101 (stem-cell-derived islet therapy) com
May 27, 2026
BEARISH
EFFECT
5/10
NewcelX Ltd.'s F-3 shelf registration (File No. 333-295770) became effective on May 15, 2026, allowing the company to of
May 18, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 4.8/10.
NEUTRAL
6-K
4/10
NewcelX Ltd. filed a 6-K furnishing the notice of meeting and proxy card for its Annual General Shar
Jun 5, 2026
BEARISH
EFFECT
5/10
NewcelX Ltd.'s F-3 shelf registration (File No. 333-295770) became effective on May 15, 2026, allowi
May 18, 2026
NEUTRAL
EFFECT
3/10
NewcelX Ltd.'s shelf registration statement (File No. 333-290516) became effective on May 6, 2026, a
May 7, 2026
BEARISH
PRESS-RELEASE
6/10
NewcelX reported FY2025 results with a net loss of $8.3M (including $5.7M non-cash finance expenses)
Apr 30, 2026
NEUTRAL
6-K
4/10
NewcelX Ltd. announced a strategic collaboration with Eledon Pharmaceuticals to combine its NCEL-101
Apr 20, 2026
BULLISH
6-K
7/10
NewcelX Ltd. (NCEL) announced a $1.35 million private placement financing at $2.75 per share, repres
Apr 1, 2026
Historical analyst distribution: 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2018-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Apr 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 27, 2026
announcement
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
<p align="center"><i>Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial</i></p>
Apr 30, 2026
earnings
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
<p align="center"><em>NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cur
Apr 20, 2026
contract
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
<p align="justify"><b>ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd</b>. (Nasdaq: NCEL), a clini
Apr 1, 2026
other
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
<p align="center"><b>Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program</b></p>